



Glaukos Announces Participation in Upcoming Investor Conferences

2024-11-08

ALISO VIEJO, Calif.--(BUSINESS WIRE)-- Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:

- Stifel Healthcare Conference on Tuesday, November 19, 2024, at 12:40 p.m. ET in New York City, NY
- Stephens Annual Investment Conference on Wednesday, November 20, 2024, at 10:00 a.m. ET in Nashville, TN
- BTIG Ophthalmology Day on Monday, December 2, 2024, at 4:40 p.m. ET (Virtual)
- Piper Sandler Annual Healthcare Conference on Wednesday, December 4, 2024, at 1:00 p.m. ET in New York City, NY
- Citi Global Healthcare Conference on Thursday, December 5, 2024, at 9:30 a.m. ET in Miami, FL

A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at <http://investors.glaukos.com>.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for *iDose® TR*, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

Chris Lewis
Vice President, Investor Relations & Corporate Affairs
(949) 481-0510
clewis@glaukos.com

Source: Glaukos Corporation